Deadline Soon: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 8, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”).

IF YOU ARE AN INVESTOR WHO LOST MONEY ON MEDPACE HOLDINGS, INC. (MEDP), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT.

What Happened?

On February 9, 2026, Medpace released its fourth quarter 2025 financial results, revealing a book-to-bill ratio of 1.04, well below the Company’s guidance of 1.15. The Company attributed the miss to backlog cancellations being “the highest they’ve been in over a year.”

On this news, Medpace’s stock price fell $84.30, or 15.9%, to close at $446.05 per share on February 10, 2026, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants: (1) consistently oversold the Company's projected book-to-bill ratio for fourth quarter 2025; (2) knew or recklessly disregarded the impact that cancellations have on the Company's book-to-bill ratio; (3) frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations were not a sign of a weak business environment; (4) reassured investors that the Company was not concerned about the lack of diversity in its pre-backlog; (5) stated that, despite the uptick in metabolic growth, the Company's upside was broad-based and not isolated to any handful of studies; and (6) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Medpace common stock between April 22, 2025 and February 9, 2026, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is June 8, 2026.

Contact Us To Participate or Learn More:

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us:

Frank R. Cruz

The Law Offices of Frank R. Cruz

2121 Avenue of the Stars, Suite 800

Century City, California 90067

Call us at: 310-914-5007

Email us at: [e-mail] our website at www.frankcruzlaw.comFollow us for updates on Twitter: twitter.com/FRC_LAW

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.